Seres Therapeutics Sinks 74% After Lead Drug Fails in Study

Updated on
  • Results from phase 2 trial weren’t statistically significant
  • Drug had been granted breakthrough therapy status by FDA

Seres Therapeutics Inc. shares lost three quarters of their value Friday after the biotechnology company said its lead experimental drug failed in a clinical trial testing it against hard-to-treat intestinal infections.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.